GENEDX HOLDINGS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.08 USD | -0.81% |
|
+14.94% | +302.91% |
| Sales 2024 * | 226M 18.84B | Sales 2025 * | 264M 22.03B | Capitalization | 289M 24.06B |
|---|---|---|---|---|---|
| Net income 2024 * | -136M -11.33B | Net income 2025 * | -107M -8.92B | EV / Sales 2024 * | 1.4 x |
| Net Debt 2024 * | 27.09M 2.26B | Net Debt 2025 * | 8.94M 745M | EV / Sales 2025 * | 1.13 x |
| P/E ratio 2024 * |
-2.27
x | P/E ratio 2025 * |
-3.2
x | Employees | 1,000 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on GeneDx Holdings Corp.
More recommendations
More press releases
| 1 day | -0.81% | ||
| 1 week | +14.94% | ||
| Current month | +21.36% | ||
| 1 month | +21.36% | ||
| 3 months | +223.98% | ||
| 6 months | +279.45% | ||
| Current year | +302.91% |
1 week
10.18
12.57
1 month
8.5312.57
Current year
2.4712.57
1 year
1.1612.57
3 years
1.16501.93
5 years
1.16896.94
10 years
1.16896.94
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 29/22/29 | |
Kevin Feeley
DFI | Director of Finance/CFO | 43 | - |
Paul Kruszka
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joshua Ruch
BRD | Director/Board Member | 74 | 22/21/22 |
| Director/Board Member | 68 | 01/22/01 | |
Keith Meister
BRD | Director/Board Member | 51 | 01/21/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 11.08 | -0.81% | 148,889 |
| 25/24/25 | 11.17 | -5.50% | 104,399 |
| 24/24/24 | 11.82 | -1.50% | 182,412 |
| 23/24/23 | 12 | +15.50% | 254,693 |
| 22/24/22 | 10.39 | +7.78% | 131,713 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
Calendar
29/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
11.08
USD
Average target price
11.38
USD
Spread / Average Target
+2.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +302.91% | 289M | |
| -17.21% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -14.57% | 1.03B |
- Stock Market
- Equities
- WGS Stock
